Gad Sophie, Le Teuff Gwenaël, Nguyen Baptiste, Verkarre Virginie, Duchatelle Veronique, Molinie Vincent, Posseme Katia, Grandon Benjamin, Da Costa Melanie, Job Bastien, Meurice Guillaume, Droin Nathalie, Mejean Arnaud, Couve Sophie, Renaud Flore, Gardie Betty, Teh Bin Tean, Richard Stephane, Ferlicot Sophie
Ecole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Mixed Research Unit (UMR) 9019, Gustave Roussy Institute, French National Scientific Research Center (CNRS), Paris-Saclay University, 94800 Villejuif, France.
Oncol Lett. 2021 Dec;22(6):835. doi: 10.3892/ol.2021.13096. Epub 2021 Oct 15.
Von Hippel-Lindau (VHL) disease is the main cause of inherited clear-cell renal cell carcinoma (ccRCC) and is caused by germline mutations in the tumor suppressor gene. Bi-allelic alterations lead to inactivation of pVHL, which plays a major role by downstream activation of the hypoxia inducible factor (HIF) pathway. Somatic mutations occur in 80% of sporadic ccRCC cases and the second most frequently mutated gene is polybromo 1 (). As there is currently no data regarding involvement in VHL disease-associated ccRCC, the aim of the present study was to assess the mutational status, and PBRM1 and HIF expression in VHL disease-associated ccRCC series compared with a sporadic series. gene was screened by Sanger sequencing for 23 VHL-disease-associated ccRCC and 22 sporadic ccRCC cases. Immunohistochemical studies were performed to detect the expression of PBRM1, HIF1 and HIF2 for all cases. In VHL-associated tumors, 13.0% (n=3/23) had somatic mutations and 17.4% (n=4/23) had a loss of PBRM1 nuclear expression. In sporadic cases, 27.3% (n=6/22) showed somatic mutations and 45.5% (n=10/22) had a loss of PBRM1 nuclear expression. Loss of PBRM1 was associated with an advanced tumor stage. HIF1-positive tumors were observed more frequently in the VHL-associated ccRCC than in the sporadic series. Furthermore, in the VHL cohort, PBRM1 expression appeared to be associated more with HIF1 than with HIF2. Given that hereditary tumors tend to be less aggressive, these results would suggest that co-expression of PBRM1 and HIF1 may have a less oncogenic role in VHL-associated ccRCC.
冯·希佩尔-林道(VHL)病是遗传性透明细胞肾细胞癌(ccRCC)的主要病因,由肿瘤抑制基因的种系突变引起。双等位基因改变导致pVHL失活,pVHL通过下游激活缺氧诱导因子(HIF)途径发挥主要作用。80%的散发性ccRCC病例存在体细胞突变,第二常见的突变基因是多溴结构域蛋白1(PBRM1)。由于目前尚无关于PBRM1参与VHL病相关ccRCC的资料,本研究的目的是评估VHL病相关ccRCC系列与散发性系列相比的PBRM1突变状态、PBRM1和HIF表达情况。通过桑格测序对23例VHL病相关ccRCC和22例散发性ccRCC病例进行PBRM1基因筛查。对所有病例进行免疫组织化学研究以检测PBRM1、HIF1和HIF2的表达。在VHL相关肿瘤中,13.0%(n = 3/23)存在体细胞突变,17.4%(n = 4/23)PBRM1核表达缺失。在散发性病例中,27.3%(n = 6/22)出现体细胞突变,45.5%(n = 10/22)PBRM1核表达缺失。PBRM1缺失与肿瘤晚期相关。在VHL相关ccRCC中观察到HIF1阳性肿瘤比散发性系列更频繁。此外,在VHL队列中,PBRM1表达似乎与HIF1的相关性比与HIF2的相关性更大。鉴于遗传性肿瘤往往侵袭性较小,这些结果表明PBRM1和HIF1的共表达在VHL相关ccRCC中可能具有较小的致癌作用。